Genetic variation at the slco1b1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 413-417

  Akao, Hironobu ^a,b   Polisecki, Eliana ^a,c   Kajinami, Kouji ^b   Trompet, Stella ^d   Robertson, Michele ^e   Ford, Ian ^e   Jukema, J Wouter ^d   de Craen, Anton J M ^d   Westendorp, Rudi G J ^d   Shepherd, James ^e   Packard, Christopher ^e   Buckley, Brendan M ^f   Schaefer, Ernst J ^a,c  

^a TUFTS UNIVERSITY   (United States)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c Leiden University Medical Centre ^*

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Low density lipoprotein cholesterol lowering response; SLCO1B1 gene; Statin

Indexed keywords

LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORGANIC ANION TRANSPORTER 2; PLACEBO; PRAVASTATIN;

AGED; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE LOCUS; GENETIC VARIABILITY; HEART INFARCTION; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; EUROPE; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; ORGANIC ANION TRANSPORTERS; ORPHAN NUCLEAR RECEPTORS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855932024     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.028     Document Type: Article

References (25)

1. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776-785.
2. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
3. Niemi M., Pasanen M.K., Neuvonen P.J. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006, 80:356-366.
4. Gerloff T., Schaefer M., Mwinyi J., et al. Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn Smiedebergs Arch Pharmacol 2006, 373:45-50.
5. Igel M., Arnold K.A., Niemi M., et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006, 79:419-426.
6. Hedman M., Antikainen M., Holmberg C., et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006, 61:706-715.
7. Tachibana-Iimori R., Tabara Y., Kusuhara H., et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004, 19:375-380.
8. Thompson J.F., Man M., Johnson K.J., et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005, 5:352-358.
9. Couvert P., Giral P., Dejager S., et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 2008, 9:1217-1227.
10. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008, 359:789-799. SEARCH Collaborative Group.
11. Voora D., Shah S.H., Spasojevic I., et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609-1616.
12. Shepherd J., Blauw G.J., Murphy M.B., et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
13. Shepherd J., Blauw G.J., Murphy M.B., et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999, 84:1192-1197.
14. Xiao L., Xie X., Zhai Y. Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism. Adv Drug Deliv Rev 2010, 62:1316-1321.
15. Havekes L.M., de Knijff P., Beisiegel U., et al. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987, 28:455-463.
16. Lahoz C., Osgood D., Wilson P.W., et al. Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study. Clin Chem 1996, 42:1817-1823.
17. Ordovas J.M., Lopez-Miranda J., Perez-Jimenez F., et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995, 113:157-166.
18. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001, 158:183-193.
19. Wilson P.W., Schaefer E.J., Larson M.G., et al. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol 1996, 16:1250-1255.
20. Lahoz C., Schaefer E.J., Cupples L.A., et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001, 154:529-537.
21. Lewontin R.C. The interaction of selection and linkage. II. Optimum models. Genetics 1964, 50:757-782.
22. Expert panel executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
23. Polisecki E., Muallem H., Maeda N., et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008, 200:109-114.
24. Polisecki E., Peter I., Robertson M., et al. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis 2008, 200:95-101.
25. Polisecki E., Peter I., Simon J.S., et al. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J Lipid Res 2010, 51:1201-1207.